Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review17-DMAG hydrochloride
Description: Water-soluble Hsp90 inhibitor
Alternative Names: NSC 707545
Chemical Name: 17-Demethoxy-17-[[2-(dimethylamino)ethyl]amino]geldanamycin hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for 17-DMAG hydrochloride
17-DMAG hydrochloride is a water-soluble analog of 17-AAG (Cat. No. 1515) and geldanamycin (Cat. No. 1368). Binds the ATP binding site of Hsp90 and inhibits its chaperone activity. Displays more potent antitumor activity than 17-AAG (mean GI50 values are 53 and 123 nM for 17-DMAG and 17-AAG respectively).
Licensing Information
Sold with the permission of the NIH, US Patent 6,890,917
Technical Data for 17-DMAG hydrochloride
| M. Wt | 653.21 |
| Formula | C32H48N4O8.HCl |
| Storage | Desiccate at -20°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 467214-21-7 |
| PubChem ID | 9852573 |
| InChI Key | DFSYBWLNYPEFJK-IHLRWNDRSA-N |
| Smiles | O=C1C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(C)/C2=O)C(C(N2)=C1)=O.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for 17-DMAG hydrochloride
References for 17-DMAG hydrochloride
References are publications that support the biological activity of the product.
Egorin et al (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and fischer 344 rats. Cancer Chemother.Pharmacol. 49 7 PMID: 11855755
Smith et al (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother.Pharmacol. 56 126 PMID: 15841378
Dote et al (2006) Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res. 66 9211 PMID: 16982765
View Related Products by Target
View Related Products by Product Action
Keywords: 17-DMAG hydrochloride, 17-DMAG hydrochloride supplier, Water-soluble, Hsp90, inhibitors, inhibits, Heat, Shock, Protein, 90, NSC707545, antibiotics, NSC, 707545, Antibiotics, 2610, Tocris Bioscience
1 Citation for 17-DMAG hydrochloride
Citations are publications that use Tocris products. Selected citations for 17-DMAG hydrochloride include:
Young et al (2015) A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Mol Med 11 113 PMID: 25700737
Reviews for 17-DMAG hydrochloride
There are currently no reviews for this product. Be the first to review 17-DMAG hydrochloride and earn rewards!
Have you used 17-DMAG hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle and DNA Damage Research Product Guide
This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:
- Cell Cycle and Mitosis
- DNA Damage Repair
- Targeted Protein Degradation
- Ubiquitin Proteasome Pathway
- Chemotherapy Targets
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.